Who We Are
Your impact at Kinnate
As the Director, Clinical Sciences you will be a
critical member of our cross-functional teams contributing to the design & execution
of clinical studies within Kinnate’s clinical programs. Your contributions will be foundational to
the safe, efficient and compliant development of our next-generation targeted oncology
therapies in early phase & advanced human clinical trials.
You will lead the collection, annotation, analysis and
interpretation of clinical study data, while ensuring integration of PK, PD,
biomarker and genomics data in partnership with R&D colleagues. You will also partner closely with Kinnate’s
R&D team to develop early-phase clinical plans in support of successful IND
submissions, lead development of clinical protocols, IBs and related plans and
documents, and provide scientific expertise to internal teams and external partners
in support of our programs.
You’ll leverage your thorough understanding of oncology drug development and your pro-active and highly developed communication skills to bring our innovative medicines to cancer patients.
New oncology therapy breakthroughs await your creative spirit and “roll-up your sleeves” approach because #patients are waiting.
This position can be located in either our San Diego headquarters or San Francisco office.
The Right Stuff
- You have an advanced degree (eg MSc or PhD degree in health science field, a PharmD or Medical degree eg MD or MBBS)
- You have a deep & sophisticated understanding of oncology drug development from pre-IND phases thru to early phase & late phase clinical development.
- You have at least 10 years of experience in oncology R&D settings, much of which includes biopharma industrial experience.
- You have at least 3 years of clinical research experience in the biopharma industry, preferably in oncology drug development programs
- You have a deep working knowledge of ICH GCP guidelines, CFR, EMA, and HIPAA regulations
- You have outstanding written & oral communication skills and presentation skills that enables clear messaging and drives programs forward
- You are recognized as a leader and have a track record of building strong collaborative partnership with diverse cross-functional team members & external partners
- You are passionately committed to bring innovative oncology drugs to patients to drive better clinical outcomes.
Kinnate Biopharma Inc. recently closed our
$276M initial public offering and are listed on Nasdaq. Prior to that, we
closed three significant venture capital financings, including our $98M Series
C round in July and August 2020 and our $74.5M Series B round in December 2019. Kinnate has a passionate and seasoned
Team, guided by industry leaders in precision medicine and drug discovery,
developing a focused portfolio strategy, and leveraging unique team
expertise. Our Research and Development team is based primarily in San
Diego, California and a portion of our management team is based in the San
Francisco Bay Area. We are a small but growing precision oncology
company with a bright future.
EEO & EMPLOYMENT ELIGIBILITY
Kinnate Biopharma Inc. is committed to building a diverse, equitable, and inclusive company. We provide equal opportunity in the terms and conditions of employment for all employees and job applicants without regard to race, color, religion, sex, sexual orientation, age, gender identity or gender expression, national origin, disability or veteran status. Kinnate Biopharma Inc. also complies with all applicable national, state and local laws governing nondiscrimination in employment as well as work authorization and employment eligibility verification requirements of applicable law.
Recruitment & Staffing Agencies: Kinnate Biopharma, Inc. does not accept unsolicited resumes from any source other than candidates. The submission of unsolicited resumes by recruitment or staffing agencies to Kinnate or its employees is strictly prohibited unless contacted directly by Kinnate’s internal HR Team. Any resume submitted by an agency in the absence of a signed agreement will automatically become the property of Kinnate, and Kinnate will not owe any referral or other fees with respect thereto.